article thumbnail

J&J, GSK and other companies knowingly marketed ineffective decongestants, lawsuits claim

Fierce Pharma

Questions first circulated about decongestant pills containing phenylephrine in 2007. Several companies, including Johnson & Johnson, GSK, Procter & Gamble and Walgreens, face class-action lawsuits that claim the drugmakers knew that over-the-counter cold and flu pills containing phenylephrine did not work as advertised.

Marketing 283
article thumbnail

Fierce Pharma Asia—Sun’s Taro buyout, Eli Lilly’s XtalPi collab, Yuhan’s cancer candidate

Fierce Pharma

Sun Pharma snapped up Taro Pharmaceutical Industries in a $307 million deal after its initial 2007 offer. Sun Pharma picked up Taro Pharmaceutical Industries 16 years after its initial offer. Eli Lilly and XtalPi linked up in a $250 million deal. | Yuhan snapped up J INTS BIO’s HER2 tyrosine kinase inhibitor (TKI) candidate.

Pharma 147
article thumbnail

Health literacy is a huge problem

World of DTC Marketing

University of Connecticut, 2007.). Through all its impacts — medical errors, increased illness and disability, loss of wages, and compromised public health — low health literacy is estimated to cost the U.S. economy up to $236 billion every year. Trujillo, S. Rosenbaum, and B. Low Health Literacy: Implications for National Health Policy.

article thumbnail

Our healthcare has failed us

World of DTC Marketing

The adult obesity rate passed 40 percent nationally for the first time according to the 2017–2018 National Health and Nutrition Examination Survey (NHANES), a 26 percent jump from 2007–2008.

article thumbnail

Study Shows Progress in Breast Cancer Survivorship Over 15 Years

Pharmacy Times

times more breast cancer survivors since the last estimate was conducted in 2007. Study shows there are 2.5

55
article thumbnail

PDA revises report on glass container manufacturing

European Pharmaceutical Review

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.” In 2007, Xyrem had an annual cost of $11,169, but in seven short years the cost had jumped to $106,215. Currently, the annual cost of Xyrem is $182,804, while Xywav is a little less at $168,508.